Compare Altria Group Inc (MO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs GeneDx Holdings Corp — how do they compare? Altria Group Inc trades at $71.54 (market cap $119.25B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Altria Group Inc is far larger — about 59× GeneDx Holdings Corp's market cap, and Altria Group Inc pays a 6.22% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 154 Days and GeneDx Holdings Corp for 19 Days on average.
| MO | WGS | |
|---|---|---|
Market Cap | $119.25B | $2.02B |
Volume | 11,178,169 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $167.51 |
52-Week Low | $54.72 | $34.51 |
Typical Hold Time | 154 Days | 19 Days |
Enterprise Value | $141.46B | $2.05B |
Dividend Yield | 6.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $71.68, up 3.31% with a bullish technical signal supported by moving averages. The stock shows strong profitability with 72.24% gross margins and 39% net income margin, though revenue has declined from $20.7B in 2022 to $20.1B in 2025. Recent earnings show mixed results with one beat and two misses in the last four quarters. The company maintains a substantial dividend yield with 60 consecutive increases, supported by $9.3B in operating cash flow.
MO presents a high-yield opportunity with analyst consensus favoring Buy ratings (61.5%), but faces significant risks including negative shareholder equity, declining margins, and regulatory pressures. The stock trades below the $69.71 consensus price target, suggesting limited upside potential. Investors must weigh the attractive 6.6% dividend yield against fundamental challenges in the core tobacco business and balance sheet concerns.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
